You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ):成都金星擬獲耀勻醫藥增資約1.128億元
格隆匯 11-15 22:06

格隆匯11月15日丨萊美藥業(300006.SZ)公佈,為進一步聚焦優勢細分領域,公司及公司持股90%的控股子公司成都金星健康藥業有限公司(“成都金星”、“目標公司”)擬與Sanum-Kehlbeck GmbH & Co. KG (“德國沙奴姆公司”)、成都耀勻醫藥科技有限公司(“耀勻醫藥”)共同簽署《成都金星健康藥業有限公司增資和認購協議》,耀勻醫藥將對成都金星進行增資,增資金額人民幣112,810,271.79元,其中人民幣28,349,358.97元計入目標公司註冊資本、增資款餘額人民幣84,460,912.82元計入目標公司資本公積。根據公司自身情況和經營規劃,公司擬放棄對成都金星的增資優先認繳權,同時,德國沙奴姆公司也放棄本次對成都金星的增資優先認繳權。

此次成都金星增資完成後,耀勻醫藥將持有目標公司61%股權、公司將持有目標公司35.1%股權、德國沙奴姆公司將持有目標公司3.9%股權,成都金星將不再納入公司合併報表範圍。

此次成都金星引入投資者耀勻醫藥有利於發揮耀勻醫藥專業優勢,助力目標公司產品滿足藥品管理辦法要求從事生產經營活動。同時,此次增資將有利於成都金星提升運營效率和經營水平,有利於公司優化資產配置,減少相關資產帶來的影響,進一步聚焦抗腫瘤、消化道、抗感染等優勢細分領域。

此次成都金星接受增資,公司放棄增資的優先認繳出資權,不會對公司的日常生產經營造成影響。根據公司持有的成都金星長期股權投資賬面價值及結合此次增資定價等因素,此次成都金星接受增資預計對公司本年度淨利潤的影響約2300萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account